SAFB2

Across TCGA pan-cancer cohorts, SAFB2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SAFB2 data layer compared with 24 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher SAFB2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SAFB2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

SKCM, LGG, and STAD are the cancer types where SAFB2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	DFS	Median	All	0.284	0.624	.001	16	view →
LGG	DFS	Median	All	0.133	0.834	<.001	12	view →
STAD	OS	Median	III,IV	0.052	0.629	<.001	12	view →
LUAD	OS	Median	III,IV	0.223	0.677	.006	9	view →
UCEC	DFS	Median	All	0.934	0.619	.017	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SAFB2–SKCM (DFS)

Open the SKCM breakdown →